Recursion Pharmaceuticals to Present at Upcoming Conferences, Showcasing TechBio Innovations

Recursion Pharmaceuticals Inc (RXRX) will participate in two investor conferences, Citi 2025 BioPharma Back to School Conference on Sept 3 and Morgan Stanley 23rd Annual Global Healthcare Conference on Sept 8. The company focuses on decoding biology to improve lives using its Recursion OS platform and one of the world's most powerful supercomputers. Participation is a strategic move to enhance visibility and potentially attract new investors.

Recursion Pharmaceuticals Inc (RXRX), a leading clinical-stage TechBio company, has announced its participation in two upcoming investor conferences in September 2025. The company will present at the Citi 2025 BioPharma Back to School Conference on September 3 and the Morgan Stanley 23rd Annual Global Healthcare Conference on September 8. Investors can access the webcasts through Recursion's investor relations website at ir.recursion.com [1].

Recursion Pharmaceuticals Inc is headquartered in Salt Lake City and is known for its innovative approach to drug discovery. The company uses its proprietary platform, Recursion OS, which leverages sophisticated machine-learning algorithms to generate vast amounts of biological and chemical data. This data is then used to identify potential therapeutic targets and accelerate the drug discovery process [2].

The participation in these conferences is seen as a strategic move to enhance visibility and potentially attract new investors. Recursion Pharmaceuticals Inc has been making significant strides in the biotech industry, with a focus on oncology and rare diseases. In 2025, the company launched Boltz-2, an AI model trained on its BioHive-2 platform, which could significantly shorten drug discovery timelines [3].

The company has also expanded its collaborations with global pharmaceutical leaders and has a strong pipeline of clinical candidates. In July 2025, Recursion Pharmaceuticals Inc acquired REV102, an oral ENPP1 inhibitor for hypophosphatasia (HPP), a disorder with no existing oral treatments. This acquisition positions the company to address a critical unmet need in the rare disease market [3].

By participating in these investor conferences, Recursion Pharmaceuticals Inc aims to provide investors with a comprehensive overview of its technology, pipeline, and strategic partnerships. The company's strong focus on AI-driven drug discovery and its robust pipeline make it an attractive investment opportunity for those in the biotech sector [2].

References:
[1] https://www.stocktitan.net/news/RXRX/recursion-to-participate-in-upcoming-investor-gxnudkebglqr.html
[2] https://www.globenewswire.com/news-release/2025/08/27/3139959/0/en/Recursion-to-Participate-in-Upcoming-Investor-Conferences.html
[3] https://finance.yahoo.com/news/recursion-pharmaceuticals-inc-rxrx-expands-090531912.html